Leadership

Learn More

Prashant Bhavar, M Pharm, LLB, PGDPL - Founder

Prashant is Founder, at VRise Therapeutics, INC. He is an accomplished pharma research professional with over a 22+ years of experience in Drug Discovery and Development Research, Inventing and Developing Novel therapeutics, establishing Drug Development collaboration, and leading Partnering activities globally. Prashant has effectively devised and implemented scientific and corporate strategies towards building a truly global successful R & D enterprises exclusively driven through creation of intellectual property assets.

Prashant as a founding team member @ Rhizen have been instrumental in successful creation and protection of respectable and credible IP of 500+ patents. As a part of key management team, Prashant has successfully handled and led several collaboration and out-licensing activities with drafting and negotiating deals worth close to USD ~750 mln.

Over the last two decades, Prashant has played pivotal role across several drug discovery assets both at Glenmark and Rhizen, including two of the most successful lead candidates, Umbralisib (Licensed to TG Therapeutics Inc and approved by USFDA under the trade name UkoniqTM*) and Tenalisib, where he is an inventor and is licensed to Curon Biopharma for Greater China Market.

Prashant has been a multitasker and has closely worked across the entire gamut of drug discovery and clinical development with stakeholders including the Scientific team, Inventors, Advisory Board members, Universities & CROs, Licensing Partners, External attorneys, and Business development teams globally. Over the last two decades, Prashant has acquired both the scientific and management skills in area of innovation and has experience spanning Research, Operations, Intellectual Property, Legal, Strategy, Business development, and an Inventor on 10+ inventions.

He started his drug discovery career with Torrent in the year 1999 and holds a M.Pharm. in Medicinal Chemistry from Birla Institute of Technology (BITS, MESRA); a Post graduate degree in Intellectual Property Management (NMIMS, Mumbai). He also holds a Law Degree (Pune University) and is a registered patent agent.

*Ukoniq is a registered Trademark of TG Therapeutics, Inc. a US based publicly listed biotech @ Nasdaq

Uday Kumar S., M Pharm, EPBM, PGDIPR - Founder

Uday Kumar S. is Founder, at VRise Therapeutics, INC. He has been an industry leader with expertise in strategic operations of biotech and a wide range of pioneering therapeutic technologies. Uday has over 18 years of academic and industry experience and a successful track record of consistently delivering products from early discovery pipeline of small molecules to late-stage products. He has worked in several therapeutic areas including Oncology, Inflammation, Metabolic disorders, Pain, and Inhalation technology, with some of the most successful biotech companies globally.

Uday is actively involved in helping biotech companies position their assets, with regulatory agencies including and not limited to USFDA, TGA, NAPHISA, HEALTH CANADA, MHRA, NMPA, AIFA, EMEA and DCGI from Pre-INDs to late-stage products. From 2010 to 2021, Uday served as founding member in Rhizen, a privately owned biotech company, last as Vice President, Scientific Affairs, where he played an instrumental role in the development and early commercialization of Umbralisib (Licensed to TG Therapeutics Inc and approved by USFDA under the trade name UkoniqTM*). He has been actively involved in discussions with regulatory agencies, for Clinical Protocols (SPAs inclusive), Fast Tracks, Orphan drugs and other expedited approvals pathways.

Earlier in his career, Uday has also worked from 2004 to 2010 at Glenmark, and at Ranbaxy and National Chemical Laboratory. His major area of interests and expertise includes Regulatory Sciences, Project Management, R&D Financing, Due Diligence, Alliance Management, Manufacturing, Quality and Clinical Operations. Uday Kumar holds a M.Pharm. (Honors) from University of Indore, a management degree from Indian Institute of Management, Lucknow, and a PGD in intellectual property rights from ICFAI.

*Ukoniq is a registered Trademark of TG Therapeutics, Inc. a US based publicly listed biotech @ Nasdaq